Cancer-Killing virus combined with immunotherapy shows promise in advanced tumors
NCT ID NCT03767348
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 2 trial tests a genetically modified herpes virus (RP1) alone or with the immunotherapy drug nivolumab in people with advanced solid tumors, including melanoma, non-small cell lung cancer, and certain skin cancers. The study aims to see if the combination is safe and can shrink tumors. About 340 participants are enrolled across multiple centers.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- RP1 (a genetically modified herpes simplex virus) and nivolumab (Opdivo, an immunotherapy drug)
- What this could lead to
- If successful, this combination could offer a new treatment option for several advanced solid tumors that are hard to treat.
- What could go wrong
- This is an early-phase trial (Phase 1/2) with a small number of participants, so results may not apply broadly. The virus-based therapy can cause side effects like flu-like symptoms and injection site reactions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CUTANEOUS MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Banner MD Anderson Cancer Center
Gilbert, Arizona, 85234, United States
-
Beatson West of Scotland Cancer Center
Glasgow, Scotland, G12 0YN, United Kingdom
-
CHU Besancon - Hopital Jean Minjoz
Besançon, 25000, France
-
CHU Dijon
Dijon, 21079, France
-
CHU de Nice Hôpital l'Archet
Nice, 06200, France
-
Carti Cancer Center
Little Rock, Arkansas, 72205, United States
-
Centre Léon Bérard Lyon
Lyon, 69373, France
-
Charité (Campus Benjamin Franklin)
Berlin, 12203, Germany
-
Clinica Universitaria de Navarra
Pamplona, 31008, Spain
-
Clínica Universidad de Navarra (Madrid)
Madrid, 28027, Spain
-
Duke Cancer Center
Durham, North Carolina, 27710, United States
-
Eccles Outpatient Care Center- Oncology Clinical Trials
Murray, Utah, 84107, United States
-
Hospital Clinic Barcelona
Barcelona, 08036, Spain
-
Hospital General Universitario de Valencia
Valencia, 46014, Spain
-
Hospital Universitari Vall d'Hebron
Barcelona, 08035, Spain
-
Hospital Universitario Virgen de la Arrixaca
Murcia, 30120, Spain
-
Hospital Universitario Virgen del Rocio
Seville, 41013, Spain
-
Hôpital Saint Louis APHP
Paris, 75010, France
-
Institut Bergonié
Bordeaux, 33076, France
-
Institut Gustave Roussy
Villejuif, 94800, France
-
Intermountain Cancer Center- Saint George Cancer Center
St. George, Utah, 84790, United States
-
James Graham Brown Cancer Center- University of Louisville
Louisville, Kentucky, 40202, United States
-
MUSC Health
Charleston, South Carolina, 29425, United States
-
Mayo Clinic
Phoenix, Arizona, 85054, United States
-
Mayo Clinic
Rochester, Minnesota, 55905, United States
-
New York University Clinical Cancer Center
New York, New York, 10016, United States
-
Oxford University Hospitals NHS Trust
Oxford, Oxfordshire, United Kingdom
-
Providence Portland Medical Center
Portland, Oregon, 97213, United States
-
Royal Marsden Hospital
London, United Kingdom
-
Seattle Cancer Care Alliance- University of Washington
Seattle, Washington, 98109, United States
-
Service de Dermatologie et Cancerologie Cutanee Hopital de la Timone
Marseille, 13005, France
-
Southampton General Hospital
Southampton, SO16 6YD, United Kingdom
-
Sylvester Comprehensive Cancer Center- University of Miami
Miami, Florida, 33136, United States
-
The Clatterbridge Cancer Centre NHS Foundation Trust
Bebington, Wirral, CH634JY, United Kingdom
-
The University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
UC San Diego
La Jolla, California, 92093, United States
-
UCLA
Los Angeles, California, 90095, United States
-
Uniklinik Marburg
Marburg, 35043, Germany
-
University Hospital Essen, Klinik für Dermatologie
Essen, 45147, Germany
-
University of Birmingham Alabama
Birmingham, Alabama, 35294, United States
-
University of California, Irvine
Orange, California, 92868, United States
-
University of California- San Francisco
San Francisco, California, 94115, United States
-
University of Cincinnati Medical Center
Cincinnati, Ohio, 45267, United States
-
University of Iowa-Cancer Center Research
Iowa City, Iowa, 52242, United States
-
University of Kiel (UKSH), Dep. of Dermatology
Kiel, 24105, Germany
-
University of Leeds- Teaching Hospital
Leeds, England, LS97TF, United Kingdom
-
University of Rochester Medical Center
Rochester, New York, 14642, United States
-
University of Southern California
Los Angeles, California, 90033, United States
-
University of Wisconsin-Carbone Cancer Center
Madison, Wisconsin, 53792, United States
-
Weill Cornell Medical College
New York, New York, 10065, United States
-
West Cancer Center
Germantown, Tennessee, 38138, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a single tracer light up cancer's first stop? a trial puts a hybrid dye-and-radioactive marker to the test.
- Could a Two-Drug combo reawaken the immune system against resistant cancers?
- Targeted drug LDK378 takes aim at rare ROS1-driven lung cancer
- Custom-Made vaccine aims to stop lung cancer recurrence
- Could starting immunotherapy earlier improve outcomes for High-Risk melanoma?
- Could a Two-Drug punch wipe out melanoma before surgery?